Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This prospective study aims to clarify the clinical efficacy and survival prognosis of
neoadjuvant immune checkpoint inhibitor (ICI) combined with chemotherapy for esophageal
cancer. It also explores predictive biomarkers and potential therapeutic targets for locally
advanced esophageal cancer based on plasma metabolomics and peripheral blood immune cell
clustering analysis. Each patient received 2-3 cycles of neoadjuvant immunotherapy with
programmed cell death 1 (PD-1) blockade in combination with albumin paclitaxel and platinum.
Exploratory analysis of plasma metabolomics combined with peripheral blood subsets of immune
cells can reveal biomarkers that predict the efficacy and prognosis of patients undergoing
neoadjuvant immunotherapy for locally advanced esophageal cancer, which also provide new
ideas for the selection of immune adjuvants and therapeutic targets in ICIs combination
therapy strategies.